Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Regulatory Flexibility On Display In Review Of Innovative Agents

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Regulatory flexibility is the backbone of FDA’s success in efficiently reviewing new drugs and biologics, especially on the frontiers of unmet medical needs, Pharmaceutical Approvals Monthly’s 2011 series of drug review profiles shows.

You may also be interested in...

FDA Considers Toxicity Profiles As Meeting Unmet Need In Melanoma

GlaxoSmithKline’s Mekinist (trametinib) and Tafinlar (dabrafenib) qualified for the regulatory benefits afforded drugs that address unmet medical needs under a broad theory introduced in FDA’s draft guidance on expedited approval pathways: offering different, but not necessarily better, toxicity profiles than marketed drugs was seen as an advantage.

Novartis Sees Targeted Combinations As Wave Of The Future In Oncology

Novartis’ targeted combination strategy in particular leverages its “strong” pipeline in agents acting on the PI3K, RAS, RAF and MEK pathways.

FDA Role In Risk Management Should Be “Broad Societal Decision,” Hamburg Says

A survey of well-informed voters conducted by the health policy institute NEHI found respondents were in favor of marketing products that might pose a risk, as long as FDA disclosed the potential dangers. Commissioner Hamburg says she is “pleased and frankly a little surprised” by the depth of appreciation for the agency’s work shown by the survey.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts